Mr. Ron Nagar reports

TEMPRAMED SIGNS EXCLUSIVE UK DISTRIBUTION AGREEMENT WITH POOLE BAY HOLDINGS FOR VIVI EPI(TM), TARGETING SCHOOL NETWORKS ACROSS THE UK

Tempramed Technologies Ltd.'s wholly owned subsidiary, Tempramed Israel Ltd., has entered into a definitive exclusive distribution agreement with Poole Bay Holdings Ltd. for VIVI Epi in the United Kingdom.

Under the agreement, Poole Bay has been appointed as the exclusive U.K. distributor of VIVI Epi, Tempramed's passive temperature protection solution designed for compatible epinephrine (adrenaline) auto-injectors. The appointment covers the U.K. market and provides a framework for local promotion, sales and customer support through Poole Bay's existing B2B (business-to-business) and digital-commerce capabilities. Commercial sales are subject to applicable U.K. regulatory registrations and requirements.

"We are delighted to have been appointed as the exclusive U.K. distributor of ViviEpi. Over the past 26 years, we have built strong relationships with more than 15,000 schools across the U.K., helping them create safer environments by providing essential products that address the practical challenges they face.

"With Benedict's Law now in place, schools are expected to have spare adrenaline auto-injectors (AAIs) available for anaphylaxis emergencies. However, storing these life-saving devices in accordance with manufacturers' recommendations, while ensuring they remain readily accessible, presents a significant challenge for schools, particularly during temperature extremes such as the prolonged heatwaves experienced this summer.

"Beyond the schools market, U.K. demand for adrenaline auto-injectors continues to grow strongly, with NHS prescriptions in England increasing by more than 40 per cent in a decade.

"We are therefore incredibly excited about ViviEpi, a highly innovative temperature protection solution that has the potential to address a significant practical challenge faced by both schools and individuals in safely storing emergency adrenaline. We look forward to introducing and promoting this technology across the U.K. as soon as the necessary regulatory registrations are complete," said Thomas Andrews, group marketing director of Poole Bay.

Approximately $198,000 (U.S.) initial two-year commercial opportunity

The agreement has an initial term of 24 months and sets minimum annual purchase targets to retain exclusivity. The aggregate minimum-volume target would represent approximately $198,000 (U.S.) in potential purchases.

The contract calls for the first purchase order to be paid in full before shipment. Annual renewals are contemplated, subject to the specified performance requirements, with minimum purchase targets increasing by 20 per cent per renewal year unless otherwise agreed. Tempramed will also support the planned launch through an allocation of sample devices for health care professional demonstrations and eligible co-marketing activities.

Poole Bay operates a U.K.-based group of specialist business-to-business e-commerce and catalogue businesses, with product ranges across first aid, medical consumables, workplace safety, personal protective equipment and related categories. Its group websites describe more than 30,000 products across 20 niche sites and a work force of more than 200 people. Brands include MediSupplies, Eureka, Koolpak and U.K. Sports Medicine. Management believes this existing commercial infrastructure can provide a practical platform to introduce VIVI Epi to relevant professional buyers, workplaces, educational institutions and consumers, subject to the distributor's launch execution.

"This agreement is strategically important because it brings VIVI Epi into the U.K. through a distribution partner whose customers already buy first-aid, medical and workplace safety products," said Ron Nagar, founder and chief executive officer of Tempramed. "Poole Bay's established on-line and catalogue channels offer a targeted route to awareness and adoption, while the minimum purchase targets create a clear commercial framework for the first two years.

"For people who rely on an adrenaline auto-injector, it is essential to carry their emergency medication while protecting it from conditions that may affect performance," Mr. Nagar added. "We see the U.K. as a meaningful market in which to build awareness of medication temperature protection and to advance our strategy of scaling through institutional and specialist distributors."

U.K. allergy market and the need for temperature protection

The U.K. Food Standards Agency has estimated that around 2.4 million adults have a clinically confirmed food allergy, illustrating the broader population affected by allergy management. Not everyone with a food allergy requires an adrenaline auto-injector and this figure should not be viewed as the addressable market for VIVI Epi.

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) advises people prescribed adrenaline auto-injectors to carry two devices at all times. Official U.K. product information for EpiPen also states that the medicine should not be stored above 25 C and should not be refrigerated or frozen, underscoring the importance of appropriate temperature management.

VIVI Epi is designed to provide reusable, passive thermal protection to compatible auto-injectors without batteries or external power. Management believes the combination of clear storage requirements, day-to-day portability and established allergy management practices supports opportunities in retail, health care adjacent, workplace and education procurement channels.

About Poole Bay Holdings Ltd.

Poole Bay is a U.K.-based group headquartered in Poole, Dorset, with established businesses in B2B e-commerce, catalogue sales, direct marketing and manufacturing. The group reports more than 30,000 products marketed through 20 specialist sites, and its portfolio includes MediSupplies, Eureka, Koolpak and other brands serving first-aid, medical, safety and workplace product customers.

About Tempramed Technologies Ltd.

Tempramed Technologies develops patented medication temperature protection solutions for people using insulin, GLP-1 therapies, epinephrine auto-injectors and other temperature-sensitive medications. Its commercial portfolio includes VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med. Tempramed is expanding through pharmacy networks, health care institutions, specialist distributors and digital health channels.

We seek Safe Harbor.